Kornimate/medical-research-clean huggingface dataset:
follicular revival in fibrosing alopecia: evaluating use of micro-needling

Conditions: Fibrosing Alopecia; Frontal Fibrosing Alopecia; Central Centrifugal Cicatricial Alopecia

Summary: to evaluate the efficacy microneedling via a professional tattoo machine in revitalizing hair follicles in patients with fibrosing alopecia.

the investigators propose an open label trial of tattoo machine microneedling in ten patients with fibrosing alopecia (five patients with ccca and five with ffa). ten healthy female patients older than 18 years will undergo 6 microneedling sessions. over the course of six months, subjects will undergo up to six treatment sessions (one session every 30 day). photographs will be taken at each session. patients will be evaluated at 8 visits over 8 months with the first visit for screening purposes. each visit will last about an hour. approximately 30 minutes will be spent on consenting and time for patient to ask questions during the first visit. the remaining 30 minutes will be allotted for the investigator to determine if the patient meets criteria for trial enrollment. during the remaining visits, 20 minutes will be allotted for photography, 15-20 minutes for the procedure and 10-15 minutes for post-procedure patient assessment. remaining 10 minutes on visits 2 and 8 will be used for biopsy.

Eligibility criteria:
inclusion criteria: * healthy female * diagnosing fibrosing alopecia exclusion criteria: * any female with hair loss for other reasons * males * patients with cardiac conditions or renal insufficiency * pregnant patients * patients containing the following who would make poor candidates for microneedling, such as skin conditions, diabetes, history of keloid formation * anything additional existing comorbidities that in the opinion of the investigator may cause unnecessary risk for the patient to participate
intraoperative oxygen concentration on incidence of surgical site infection

Conditions: Surgical Site Infection

Summary: surgical site infections (ssi) are the most common healthcare-associated infections and sources of morbidity and over-mortality. factors that have been proven to reduce ssi include antimicrobial prophylaxis, maintenance of perioperative normothermia, avoidance of hyperglycemia, proper surgical techniques, and adequate pain relief postoperatively

in 2016, a systematic review and meta-analysis assessing the effects of systematic high fio2 (80%) compared with standard fio2 (30%) concluded that high fio2 was associated with a reduction of ssi in patients undergoing surgery under general anesthesia. consequently, the who recommended that "adult patients undergoing general anesthesia should receive an 80% fio2 intra-operatively to reduce the risk of ssi".these recommendations have sparked a large debate on the benefits and harms of hyperoxemia. from the theoretical point-of-view, several pro (prevention of hypoxemia, ssi, and postoperative nausea and vomiting) and con (respiratory adverse events, increased production of harmful "reactive oxygen species") arguments have been raised by believers and detractors of high fio2. accordingly, and despite these recommendations, anesthetists still used a wide range of intraoperative fio2 in daily practice and frequently changed fio2 settings during surgery unrelated to patients' pao2 or spo2. the proxi study, the largest multicenter randomized controlled trial specifically designed to assess the role of high vs. low intraoperative fio2 on ssi, did not report any reduction of the incidence of ssi with the administration of 80% fio2 during colorectal surgery. similarly, the recent multicenter randomized iprove-o2 trial that included 740 patients undergoing major abdominal surgery, ventilated intraoperatively with an evidence-based protective strategy, reported a similar ssi rate between the 30% and 80% fio2 groups.

Eligibility criteria:
inclusion criteria: * - bmi of \<35 kg/m2 * scheduled for elective abdominal laparotomy/ laparoscopy under general anesthesia with an expected surgical time longer than 2 h. * asa i and ii exclusion criteria: * - patients undergoing minor procedures, where the expected duration of surgery will be less than 1 hour. * emergency surgeries for bowel obstruction. * abdominal surgery for vascular or plastic indications. * patients with a recent history of fever, * patients with uncontrolled diabetes mellitus, * patient with known immunological dysfunction (on steroids, decompensated liver disease, hiv, etc.).
tezepelumab pro study

Conditions: Asthma

Summary: this study assesses the impact of tezepelumab treatment not only on asthma control but also on cough specific health-related quality of life (hrqol). asthma control can be evaluated using asthma control questionnaire (acq). cough symptom which is one of the symptoms related airway hyperresponsiveness can be assessed via the relevant questionnaire, leicester cough questionnaire (lcq). there is moderate negative correlation between acq and lcq . improvements in both asthma control and cough symptom by tezepelumab would clarify effectiveness of tezepelumab in real-world. though tezepelumab is recently approved in japan, there is no real-world evidence on tezepelumab, particularly on above mentioned symptoms. thus, this study aims to estimate effectiveness of tezepelumab on asthma and cough symptoms in real world settings.


Eligibility criteria:
inclusion criteria: 1. patients aged ≥18 years who provide informed consent and who receive new prescription of tezepelumab as per the physician's decision at baseline according to the package insert saying "tezepelumab is given to patient with asthma (limited to severe or refractory patient whose asthma symptoms cannot be controlled even with existing treatment)" 2. acq-6 ≥1.5 at baseline 3. patients with persistent cough ≥8 weeks up until the baseline visit according to the japanese respiratory society guidelines for the management of cough and sputum 2019 exclusion criteria: 1. patients who had asthma exacerbation within one month before study enrollment 2. patients who had the biologics treatment in following period prior to the enrollment * omalizumab in 2 or 4 weeks depending on the body weight and total ige amount * mepolizumab in 4 weeks * benralizumab in 8 weeks * dupilumab in 2 weeks 3. patients with cough related diseases other than asthma as determined by treating physicians 4. patients participating in studies that affect this study (study with other interventional treatment to evaluate efficacy/safety of treatment in patients with cough, asthma, or allergic/eosinophilic diseases) 5. any disorder, including heart failure, malignancy, morbid obesity(bmi≧35) , respiratory infectious disease that is not stable (e.g. patients who need medical treatment) in the opinion of the investigator and could: * affect the safety of the patient throughout the study * impede the patient's ability to complete the entire duration of study 6. patients with pregnancy or lactation period
a disease area study on the awareness and perceptions of systemic inflammation and hscrp as a biomarker in patients with ascvd and ckd in china among cardiologists and nephrologists

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)

Summary: this is a survey-based study with the objective to understand the awareness, perceptions and potential clinical management patterns among chinese cardiologists and nephrologists towards the role of systemic inflammation in patients with ascvd and ckd in real-world clinical setting.


Eligibility criteria:
inclusion criteria: * work in cardiology, internal medicine, or nephrology department * specialize in one of the following: coronary interventional cardiology, hf, general cardiology, preventive cardiology, cardiac rehabilitation or nephrology * practice at consultant level for 3+ years after standardized training for resident physicians or 3+ years' working experience as a specialist * manage at least 20 adult patients with ascvd and ckd (not dialysis-only) every month exclusion criteria: * unwilling to provide informed consent * insufficient number of patients with ascvd and ckd * do not fulfil inclusion criteria.
a phaseⅱ/ ⅲ seamless study to evaluate efficacy and safety of paracetamol injection as adjuvant to morphine-based postoperative analgesia

Conditions: Post-operative Analgesia

Summary: paracetamol,a classical analgesic agent,constitutes an essential component of multi-modal analgesia. this medication is generally safe, well tolerated and effective within recommended daily dose.the purpose of the study is to evaluate the efficacy and safety of paracetamol injection as adjuvant to morphine-based post-operative analgesia, as well as to explore the reasonable dosage of paracetamol among chinese population under above-mentioned circumstance.


Eligibility criteria:
inclusion criteria: * aged from 18 to 70 years inclusively, male or female; * patients scheduled for open abdominal surgery(such as gall bladder, lower abdominal investigative surgery), gynecologic surgery(such as trans-abdominal hysterectomy), orthopedic surgery(such as replacement and reconstruction of knee, hip or shoulder joint), with anticipated need for post-operative iv. morphine analgesia≥24h; * 18kg/m2≤bmi≤30 kg/m2; * classified as asa risk class i, ii according to the american society of anesthesiologists; * able to understand the study procedures and the use of the pain scales, able to operate a patient controlled analgesia (pca) device and to communicate meaningfully with the study observer and staff; * patients free of any contraindication to the study drugs, morphine and to the standardized anesthesia protocol; * clearly understand the procedure of study, voluntarily participate and provided written consent form. exclusion criteria: * impaired liver function (alt and/or ast \> 2 x upper limit of normal range, or tbil≥1.5 x upper limit of normal range); * impaired renal function(serum creatinine \>176μmol/l), or undergoing dialysis within 28 days before surgery; * patients at high risk for bleeding, including congenital hemorrhagic disease(such as hemophilia), thrombocytopenia(cbc plt\<30×109/l), qualitative plateletdefects(such as itp, dic, congenital abonormal platelet), or clinically significant active bleeding; * abnormal resting ecg, judged as not eligible for entry by investigator; * hypertensive patients not achieving satisfactory bp control under hypertensive medication(sitting sbp≥160mm hg, and/or dbp≥105mm hg during screen period); * sitting sbp≤90mm hg during screening period; * diabetic patients not achieving satisfactory blood glucose control(fbg≥11.1mol/l during screening period); * known history of bronchial asthma, pulmonary heart disease or heart failure; * participation in other trials within 30 days; * pregnant women or women in lactation; * patients not eligible due to other reasons judged by the investigator.

Keywords: paracetamol post-operative analgesia
diabetes mellitus - a diagnosis trial by means of non invasive measurements

Conditions: Diabetes Mellitus Type II

Summary: vascular damage caused by diabetes mellitus, cigarette smoking, age and arterial hypertension theoretically changes pulse wave velocity.

diabetes mellitus related vascular alterations are associated with an increased risk of hypertonia, atherosclerosis, neuropathy, diabetic retinopathy, and further more. increased vascular rigidity, which is based on the increased stiffness of vessels caused by vascular damage leads to an increase of pulse wave velocity. this assumption is based on the moens-korteweg-equation which is calculated using the modus of arterial vessel elasticity, arterial vessel wall thickness, the arterial radius and blood viscosity.

Eligibility criteria:
inclusion criteria: * patients over 18 years exclusion criteria: * diabetic foot gangrene * no possibility of pulse wave velocitiy measurement on the finger or toe

Keywords: pulse walve arrival time differences
treatment of latent tuberculosis in socially marginalised citizens

Conditions: Compliance, Patient

Summary: an open-label, randomised controlled trial comparing compliance to treatment for latent tuberculosis infection in socially marginalised citizens. participants will be randomized to either daily isoniazid for 6 months or weekly rifapentine and isoniazid as directly observed therapy for twelve weeks.

eligible participants will be randomised to receive either daily isoniazid for 6 months with monthly visits for pill count, evaluation of adverse events and dispensing of isoniazid for the next month, or weekly doses of rifapentine and isoniazid for twelve weeks as direct observed therapy where the drugs are administered in the presence of a study nurse or doctor. control bloodsamples (alat, alkaline phosphatase, bilirubin, inr, haemoglobin, trombocytes and leukocyte differential count) will be taken at baseline and at least once during treatment in the rifapentine and isoniazid group and at least twice in the isoniazid-only group. one year after treatment completion participants will be called in for evaluation for active tuberculosis.

Eligibility criteria:
inclusion criteria: * reporting to be homeless (independent of whether the person has an official address) or regularly seeking homeless shelters or public institutions to supply basic needs * ltbi defined by positive igra test * found plausible by study doctor that the person has been exposed to tuberculosis within 2 years * aged 18 years or older exclusion criteria: * previously treated for tuberculosis * pregnant or breastfeeding * active tuberculosis (evaluated by chest x-ray and examination by a trained doctor) * unable to give informed consent * tested positive for ltbi as part of contact investigation where the index case has or is suspected to have inh of rif resistant tb * known hiv on antiretroviral treatment * porphyria * known allergy to rifamycins or isoniazid * known epilepsy * known liver disease causing affected liver parameters (alat, alkaline phosphatase, bilirubin, inr) * any lab abnormality, disease, concomitant medication or condition that, in the opinion of the investigator, excludes a person from participating
basal cell carcinoma recurrence after mohs surgery

Conditions: Basal Cell Carcinoma

Summary: basal cell carcinoma (bcc) is the most common skin cancer in the us and can cause significant adverse effects. mohs micrographic surgery, the treatment of choice for higher risk bcc, allows for removal of lesions with preservation of healthy tissue. although the bcc recurrence rate post mohs surgery is estimated at 1-2%, recent data is lacking to validate this historical measurement. our purpose is to determine the current recurrence rate of bcc after mohs surgery.

basal cell carcinoma (bcc) is the most common nonmelanoma skin cancer in the united states, affecting nearly one million of all americans. while bcc is rarely mortal, it has significant associated physical, psychological, and monetary costs to patients such as disfigurement and sensory loss. individuals who have been diagnosed with at least one bcc lesion are likely to be diagnosed with more in the future. treatment of these lesions and recurrent physician appointments can be a great inconvenience to patients, resulting in expenses to patients and loss of work and family time. the mohs surgery technique is associated with a low recurrence rate for bcc and is preferred for higher risk tumors and for tumors in cosmetically sensitive sites on the head and neck. while recurrence rates of bcc post mohs are 1-2% for primary basal cells, recent data is not available to validate this historical assessment. currently, comprehensive rates of recurrence are not available because a national registry of recurrence rates for bcc and squamous cell carcinoma (scc) does not exist. the purpose of this study is to both historically and prospectively assess current basal cell carcinoma recurrence rates in patients undergoing mohs micrographic surgery.

Eligibility criteria:
inclusion criteria: * subjects with bcc lesions on the head, neck, genitalia, hands, or feet * subjects who have undergone mohs micrographic surgery for bcc on or before december 31, 2006 * subjects with a medical record at the respective site * subjects in a stable health condition, as determined by the principle investigator exclusion criteria: * subjects with basal cell nevus syndrome * subjects with lesions only in areas other than the head, neck, genitalia, * hands and feet * subjects who have not followed up through the department of dermatology * subjects with recurrent bcc lesions diagnosed on or prior to the recorded date of mohs surgery

Keywords: skin cancer basal cell mohs surgery
influence of esophageal washout on local carcinoma recurrence after curative resection

Conditions: Esophageal Neoplasms

Summary: the locare-trial is an investigator initiated, randomized-controlled trial with two parallel arms (n=60 each) and investigates the influence of esophageal washout on long-term outcomes in patients undergoing elective esophageal resection for carcinoma. the primary endpoint is defined as local carcinoma recurrence. secondary endpoints will be locoregional and distant recurrence, disease-specific survival and esophageal cancer specific survival.

treatment of squamous cell carcinoma and adenocarcinoma of the esophagus has changed rapidly over the last decades due to implementation of multimodal cancer therapies such as radiotherapy or combined radiochemotherapy. surgery, however, still is the mainstay of curative treatment options for this cancer entity. due to the significant improvement in surgical technique and perioperative management, the postoperative mortality rate has fallen to about 5% with an estimated 5-year survival of 35%. nevertheless, patients after esophagectomy are at high risk for local recurrence especially within the first 2 years after treatment. independent risk factors for the development of carcinoma recurrence are incomplete resection (r1), extracapsular lymph node involvement and postoperative complications. exfoliated, malignant cells remaining in luminal organs like the esophagus or colorectum could present another important risk factor for local recurrence especially at the site of anastomosis. in the treatment of rectal cancer, data have shown, that intraoperative rectal washout significantly reduces the risk of local recurrence from about 10% to 5%. for this reason, rectal washout during anterior resection has become a standard in many surgical institutions. besides agents like cetrimide, sodium hypochlorite, formalin or saline, povidone-iodine has also been used for rectal mucosal application in prospective studies. questions arise, weather similar positive outcomes could be achieved in esophageal surgery. the investigators hypothesize that esophageal washout with a povidone-iodine solution (betaisodona®, mundipharma) reduces the risk of local carcinoma recurrence after radical resection.

Eligibility criteria:
inclusion criteria: * patients scheduled for elective esophageal resection or esophagectomy * age equal or greater than 18 years * written informed consent * squamous cell carcinoma of the esophagus (scc) * adenocarcinoma of the gastroesophageal junction (aeg) type i exclusion criteria: * local irresectability or metastatic disease * adenocarcinoma of the gastroesophageal junction type ii and iii * histopathological r1-resection * surgery for recurrence * iodine allergy * hyperthyreosis
dandelion juice in the treatment of dyshidrotic hand eczema

Conditions: Vesicular Palmoplantar Eczema; Pompholyx

Summary: dandelion juice has been used in herbal medicine for at least 1000 years. vesicular hand eczema is a rare, but difficult to treat, type of hand eczema. one case report has shown that ingestion of dandelion juice could induce a beneficial effect on this type of eczema. the purpose of this study is to test whether this effect can be retrieved in other patients.

dandelion juice has been used in herbal medicine for at least 1000 years. one case report has shown a beneficial effect of this herbal remedy on dyshidrotic hand eczema, and the purpose of this pilot study is to test whether this effect can be retrieved in other patients. the patients are recruited from our out-patient clinic. only patients with negative patch tests to compositae are offered treatment with dandelion juice for 20-30 days.

Eligibility criteria:
inclusion criteria: * adult patients with dyshidrotic eczema for at least 1 year and negative patch test reactions to compositae (tested within the last 3 years) and normal renal and hepatic blood tests. exclusion criteria: * treatment with systemic steroids or other immunosuppressive/-modulating drugs, including uv therapy, within the last 3 months. * pregnancy, lactation. * compositae contact allergy. * liver or gall bladder disease. * abnormal renal or hepatic blood tests.

Keywords: dandelion herbal remedy hand eczema compositae
duration of sciatic nerve block after injection of local anesthetic in or around the nerve

Conditions: Orthopedic Surgical Procedures; Postoperative Pain

Summary: this study was designed to assess whether the injection of local anesthetic into the nerve (intraneural), as opposed to around it (perineural), leads to longer anesthesia and analgesia of the leg. some reports of accidental intraneural injection mention an extremely long duration. when different drugs and doses were evaluated in a clinical trial of intraneural injection, a longer-than-expected duration was reported. the investigators will compare the two types of injection using the same drug, so as to determine if there is an actual difference in duration.

this randomized, controlled trial will investigate prospectively for differences in sensory and motor block duration after intra- or perineural injection of 1.5% (wt/vol) mepivacaine, a short-acting local anesthetic.

Eligibility criteria:
inclusion criteria: * undergoing non-emergent orthopedic procedure of knee, leg, foot with thigh tourniquet * asa physical status class i-iii * consenting to surgery under peripheral nerve block anesthesia (sciatic + femoral/saphenous block) exclusion criteria: * unable to understand or communicate for the purpose of the study * exhibiting signs of neuropathy in the ipsilateral extremity * inability to satisfactorily image the sciatic nerve in the opinion of the attending anesthesiologist

Keywords: lower extremity sciatic nerve anesthesia, regional anesthetics, local mepivacaine ultrasonography